|
|
Market Analysis and Prospect of Gene Therapy Industry |
FENG Xue-jiao1,**(),HENG Chao1,YU Xin-yu2,WANG Jun-shu1 |
1 Institute of Science and Technology Strategy, Jiangxi Academy of Sciences, Nanchang 330096,China 2 School of Public Policy and Administration, Nanchang University, Nanchang 330096, China |
|
|
Abstract Gene therapy provides a new strategy for the treatment of major refractory diseases with a promising market outlook. By of the end of 2022, a total of 45 gene therapy drugs around the world were approved to be listed, and more than 3 000 drugs were in clinical trials. There are also 4 types of domestic gene therapy products available in China. Currently, the top three leading enterprises in the world account for more than 50% of the market share. As there is an increasing number of patients with rare diseases and tumors in China year by year, the domestic gene therapy market continues to grow. Driven by industry development policies, a number of enterprises such as Yao Ming Ju Nuo, Legend Biology, and Keji Biology have emerged and achieved certain progress. With the gradual improvement of policies, the deepening of scientific research, and the lowering of treatment costs, gene therapy is expected to become a conventional and safe treatment.
|
Received: 14 April 2023
Published: 04 July 2023
|
|
|
|
[1] |
Gruntman A M, Flotte T R. The rapidly evolving state of gene therapy. The FASEB Journal, 2018, 32(4): 1733-1740.
doi: 10.1096/fsb2.v32.4
|
|
|
[2] |
Cho S W, Kim S, Kim J M, et al. Targeted genome engineering in human cells with the Cas 9 RNA-guided endonuclease. Nature Biotechnology, 2013, 31(3): 230-232.
doi: 10.1038/nbt.2507
|
|
|
[3] |
Ginn S L, Amaya A K, Alexander I E, et al. Gene therapy clinical trials worldwide to 2017: an update. J Gene Med, 2018, 20: e3015.
doi: 10.1002/jgm.v20.5
|
|
|
[4] |
Weβ L, Schnieders F. Immuno-oncology-the translational runway for gene therapy: gene therapeutics to address multiple immune targets. Human Gene Therapy, 2017, 28(12): 1130-1137.
doi: 10.1089/hum.2017.145
pmid: 29061083
|
|
|
[5] |
Wei J, Xiao M, Mao Z K, et al. Outcomes of relapsed/refractory aggressive B-cell non-Hodgkin lymphoma (r/r B-NHL) patients with TP53 gene disruption treated with CD19/22 cocktail CAR T-cell therapy alone or incorporated with autologous stem cell transplantation (ASCT). Blood, 2021, 138: 94.
doi: 10.1182/blood-2021-147278
|
|
|
[6] |
Ma C C, Wang Z L, Xu T, et al. The approved gene therapy drugs worldwide: from 1998 to 2019. Biotechnology Advances, 2020, 40: 107502.
doi: 10.1016/j.biotechadv.2019.107502
|
|
|
[7] |
张永理, 张开然. 我国罕见病患者医疗保障现状及改进建议. 卫生经济研究, 2023, 40(1):53-56, 60.
|
|
|
[7] |
Zhang Y L, Zhang K R. Medical security status and improvement suggestions for patients with rare diseases in China. Health Economics Research, 2023, 40(1):53-56, 60.
|
|
|
[8] |
Zheng R S, Zhang S W, Zeng H M, et al. Cancer incidence and mortality in China, 2016. Journal of the National Cancer Center, 2022, 2(1): 1-9.
doi: 10.1016/j.jncc.2022.02.002
|
|
|
[9] |
解国涛, 晏贤春, 韩骅, 等. 单碱基编辑技术在单基因遗传病治疗中的应用研究进展. 基因组学与应用生物学, 1-18.[2023-05-29]. http://kns.cnki.net/kcms/detail/45.1369.Q.20230130.1442.001.html.
|
|
|
[9] |
Xie G T, Yan X C, Han H, et al. Research progress on the application of single base editing technology in the treatment of single gene genetic diseases. Genomics and Applied Biology, 1-18.[2023-05-29]. http://kns.cnki.net/kcms/detail/45.1369.Q.20230130.1442.001.html.
|
|
|
[10] |
刘旭, 仲祉霖, 钟涛. 碱基编辑器的研发及其应用. 中国细胞生物学学报, 2022, 44(12):2294-2304.
|
|
|
[10] |
Liu X, Zhong Z L, Zhong T. Development and application of base editor. Chinese Journal of Cell Biology, 2022, 44(12):2294-2304.
|
|
|
[11] |
刘尧, 周先辉, 黄舒泓, 等. 引导编辑: 突破碱基编辑类型的新技术. 遗传, 2022, 44(11): 993-1008.
|
|
|
[11] |
Liu Y, Zhou X H, Huang S H, et al. Prime editing: a search and replace tool with versatile base changes. Hereditas (Beijing), 2022, 44(11): 993-1008.
|
|
|
[12] |
Friedmann T, Roblin R. Gene therapy for human genetic disease? Science, 1972, 175(4025): 949-955.
doi: 10.1126/science.175.4025.949
pmid: 5061866
|
|
|
[13] |
陈伟伟, 杨胜果, 刘毅. 人体胚胎基因编辑的伦理及法律问题研究: 以 “基因编辑婴儿” 事件为分析对象. 科技与法律, 2019(2): 61-65, 73.
|
|
|
[13] |
Chen W W, Yang S G, Liu Y. Study on ethical and legal issues of human embryo gene editing: taking the event of “genetically-edited babies” as the analysis object. Journal of Science, Technology and Law, 2019(2): 61-65, 73.
|
|
|
|
Viewed |
|
|
|
Full text
|
|
|
|
|
Abstract
|
|
|
|
|
Cited |
|
|
|
|
|
Shared |
|
|
|
|
|
Discussed |
|
|
|
|